Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
A Hoos, R Ibrahim, A Korman, K Abdallah… - Seminars in …, 2010 - Elsevier
Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-
cell activity led to development of the fully human, monoclonal antibody ipilimumab to block
CTLA-4 and potentiate antitumor T-cell responses. Animal studies first provided insight into
the ability of an anti–CTLA-4 antibody to cause tumor regression, particularly in combination
regimens. Early clinical studies defined ipilimumab pharmacokinetics and possibilities for
combinability. Phase II trials of ipilimumab in advanced melanoma showed objective …
cell activity led to development of the fully human, monoclonal antibody ipilimumab to block
CTLA-4 and potentiate antitumor T-cell responses. Animal studies first provided insight into
the ability of an anti–CTLA-4 antibody to cause tumor regression, particularly in combination
regimens. Early clinical studies defined ipilimumab pharmacokinetics and possibilities for
combinability. Phase II trials of ipilimumab in advanced melanoma showed objective …